Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALLR NASDAQ:BHST NASDAQ:CYPH NYSE:JATT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALLRAllarity Therapeutics$1.41+0.7%$1.18$0.77▼$2.35$21.78M0.38162,614 shs272,325 shsBHSTBioHarvest Sciences$4.21-0.1%$4.35$4.10▼$12.80$82.54M0.8127,166 shs9,350 shsCYPHCypherpunk Technologies$1.10+2.3%$0.76$0.23▼$3.70$106.96M-0.092.78 million shs15.98 million shsJATTJATT Acquisition$10.56-3.4%$7.16$9.99▼$11.31$82.36MN/A15,035 shs621 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALLRAllarity Therapeutics+7.69%+2.19%+20.69%+66.19%+32.08%BHSTBioHarvest Sciences-2.64%-2.09%-1.64%-10.43%-33.91%CYPHCypherpunk Technologies+9.94%+18.23%+40.16%+50.70%+179.74%JATTJATT Acquisition0.00%+0.94%+78.28%+89.26%+631.29%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALLRAllarity Therapeutics$1.41+0.7%$1.18$0.77▼$2.35$21.78M0.38162,614 shs272,325 shsBHSTBioHarvest Sciences$4.21-0.1%$4.35$4.10▼$12.80$82.54M0.8127,166 shs9,350 shsCYPHCypherpunk Technologies$1.10+2.3%$0.76$0.23▼$3.70$106.96M-0.092.78 million shs15.98 million shsJATTJATT Acquisition$10.56-3.4%$7.16$9.99▼$11.31$82.36MN/A15,035 shs621 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALLRAllarity Therapeutics+7.69%+2.19%+20.69%+66.19%+32.08%BHSTBioHarvest Sciences-2.64%-2.09%-1.64%-10.43%-33.91%CYPHCypherpunk Technologies+9.94%+18.23%+40.16%+50.70%+179.74%JATTJATT Acquisition0.00%+0.94%+78.28%+89.26%+631.29%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALLRAllarity Therapeutics 2.00Hold$9.75591.49% UpsideBHSTBioHarvest Sciences 2.00Hold$10.00137.70% UpsideCYPHCypherpunk Technologies 1.00SellN/AN/AJATTJATT Acquisition 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ALLR, BHST, CYPH, and JATT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/22/2026CYPHCypherpunk Technologies Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D) ➝ Sell (D+)4/20/2026ALLRAllarity Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/10/2026ALLRAllarity Therapeutics Ascendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$9.50 ➝ $9.753/27/2026BHSTBioHarvest Sciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)2/19/2026BHSTBioHarvest Sciences Roth MkmSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$10.00(Data available from 5/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALLRAllarity Therapeutics$320K68.12N/AN/A$0.61 per share2.31BHSTBioHarvest Sciences$34.51M2.39N/AN/A$1.30 per share3.24CYPHCypherpunk TechnologiesN/AN/AN/AN/A$1.83 per shareN/AJATTJATT AcquisitionN/AN/A$0.39 per share27.08($0.53) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALLRAllarity Therapeutics-$11.23M-$0.80N/AN/AN/AN/A-85.29%-49.92%5/8/2026 (Estimated)BHSTBioHarvest Sciences-$11.14M-$0.61N/AN/AN/A-32.27%-136.42%-27.92%5/14/2026 (Estimated)CYPHCypherpunk Technologies$4.82M$0.0715.64N/AN/AN/A-99.76%-79.44%5/18/2026 (Estimated)JATTJATT Acquisition$6.85MN/AN/AN/AN/AN/A-49.58%2.84%N/ALatest ALLR, BHST, CYPH, and JATT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/18/2026Q1 2026CYPHCypherpunk Technologies-$0.0406N/AN/AN/AN/AN/A5/14/2026Q1 2026BHSTBioHarvest Sciences-$0.13N/AN/AN/A$8.50 millionN/A5/8/2026N/AALLRAllarity Therapeutics-$0.22N/AN/AN/A$0.32 millionN/A3/30/2026Q4 2025ALLRAllarity Therapeutics-$0.22-$0.21+$0.01-$0.21N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthALLRAllarity TherapeuticsN/AN/AN/AN/AN/ABHSTBioHarvest SciencesN/AN/AN/AN/AN/ACYPHCypherpunk TechnologiesN/AN/AN/AN/AN/AJATTJATT AcquisitionN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALLRAllarity TherapeuticsN/A2.132.13BHSTBioHarvest Sciences0.103.973.38CYPHCypherpunk TechnologiesN/A35.5635.56JATTJATT AcquisitionN/A0.150.15Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALLRAllarity Therapeutics11.53%BHSTBioHarvest SciencesN/ACYPHCypherpunk Technologies30.46%JATTJATT Acquisition47.97%Insider OwnershipCompanyInsider OwnershipALLRAllarity Therapeutics0.01%BHSTBioHarvest SciencesN/ACYPHCypherpunk Technologies4.30%JATTJATT Acquisition20.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALLRAllarity Therapeutics1015.46 million15.82 millionNot OptionableBHSTBioHarvest SciencesN/A19.62 millionN/AN/ACYPHCypherpunk Technologies4097.68 million86.11 millionOptionableJATTJATT Acquisition37.80 million13.80 millionNot OptionableALLR, BHST, CYPH, and JATT HeadlinesRecent News About These CompaniesJATT II Acquisition Corp Announces Closing of $60,000,000 Initial Public OfferingApril 20, 2026 | globenewswire.comJATT II Acquisition Corp.April 19, 2026 | edition.cnn.comAmanat Acquisition Files for $75M IPOApril 17, 2026 | marketwatch.comJATT II Acquisition Corp prices $60 million IPO at $10 per shareApril 17, 2026 | investing.comJATT II Acquisition Corp Announces Pricing of $60,000,000 Initial Public OfferingApril 16, 2026 | globenewswire.comJatt II Acquisition Files for IPOMarch 13, 2026 | marketwatch.comCautious Hold Rating on Zura Bio Due to Efficacy Concerns and Competitive RisksDecember 25, 2024 | markets.businessinsider.comZura Bio (ZURA) Receives a Buy from Piper SandlerDecember 12, 2024 | markets.businessinsider.comCautious Outlook on Zura Bio: Neutral Rating Due to Clinical Challenges and Financial UncertaintyNovember 11, 2024 | markets.businessinsider.comThe Legend of Maula Jatt Review: Fawad Khan’s GoT-Coded War Epic Is Derivative, RIdden With ClichesOctober 4, 2024 | moneycontrol.comRelease of Fawad Khan’s Pakistani blockbuster ‘The Legend of Maula Jatt’ halted in IndiaOctober 4, 2024 | thehindu.comPakistani hit The Legend of Maula Jatt, starring Fawad Khan, Mahira Khan, not to release in India, confirms distributorOctober 4, 2024 | hindustantimes.comHIndia puts blockbuster Pakistani film on holdOctober 4, 2024 | bbc.co.uk"What is need to release Pakistani film in India?" Shiv Sena (UBT) opposes release of 'The Legend of Maula Jatt'September 22, 2024 | malaysiasun.comMShiv Sena (UBT) leader Anand Dubey opposes release of Pakistani film 'The Legend of Maula Jatt' in IndiaSeptember 22, 2024 | malaysiasun.comM‘Jatt & Juliet 3’ OTT release: When and where to watch the Diljit Dosanjh and Neeru Bajwa starrer rom-comAugust 27, 2024 | timesofindia.indiatimes.comBahdarpur Jatt Pin CodeApril 9, 2024 | indiatvnews.comINishikant Dubey, wife booked in med college acquisition caseMarch 31, 2024 | timesofindia.indiatimes.comSen. Fetterman says he will use ‘whatever tools are in the box’ to stop Japanese acquisition of U.S. SteelDecember 22, 2023 | pennlive.comPMicrosoft poised to close massive Activision Blizzard acquisition next weekOctober 9, 2023 | vg247.comVNew MarketBeat Followers Over TimeMedia Sentiment Over TimeALLR, BHST, CYPH, and JATT Company DescriptionsAllarity Therapeutics NASDAQ:ALLR$1.41 +0.01 (+0.71%) As of 02:20 PM Eastern This is a fair market value price provided by Massive. Learn more.Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. Allarity Therapeutics, Inc. has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors. The company was incorporated in 2004 and is headquartered in Boston, Massachusetts.BioHarvest Sciences NASDAQ:BHST$4.21 0.00 (-0.07%) As of 02:08 PM Eastern This is a fair market value price provided by Massive. Learn more.BioHarvest Sciences Inc. is a biotech firm. It focused on leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions, within business verticals nutraceutical health and wellness products such as dietary supplements and development of plant cell-based Active Pharmaceutical Ingredients which focus on specific medical indications. BioHarvest Sciences Inc. is based in Vancouver, Canada.Cypherpunk Technologies NASDAQ:CYPH$1.10 +0.03 (+2.34%) As of 02:05 PM EasternLeap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with NovaRock, Adimab, and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.JATT Acquisition NYSE:JATT$10.56 -0.37 (-3.39%) As of 02:19 PM Eastern This is a fair market value price provided by Massive. Learn more.JATT Acquisition Corp does not have significant operations. It intends to effect a merger, capital share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company intends to focus on businesses primarily operating in the life sciences sector. JATT Acquisition Corp was incorporated in 2021 and is based in Grand Cayman, the Cayman Islands. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Boarding Passes Now Being Issued for the Ultimate eVTOL Arbitrage Years in the Making, AMD’s Upside Movement Has Just Begun Western Digital: The Storage Behemoth Skyrocketing on AI Demand Old Money, New Tech: Western Union's Crypto Reboot Pinterest Pins a Profit Play To Its Mood Board Just How Big a Problem Could Amazon’s Cash Burn Rate Be? BlackBerry Rewrites Its Own Operating System Grab Holdings Faces Hurdles, But Upside Potential Is Hard to Ignore Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
